NWM
ZYNE

Northwest Wealth Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Northwest Wealth Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200
Closed -$1K – 496
2019
Q1 		$1K Buy
+200
New +$973 ﹤0.01% 511

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northwest Wealth Management's ZYNE Position: Q2 2019 in Review

Northwest Wealth Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 200 shares — an estimated $1K sold.

Northwest Wealth Management first reported a position in ZYNE in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

  • Northwest Wealth Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
  • Northwest Wealth Management sold 200 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $1K.
  • Northwest Wealth Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2019 and held it in 1 quarter.
  • Northwest Wealth Management's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on Northwest Wealth Management's 13F filing for Q2 2019, filed 23 Jul 2019.